(Q36298955)

13 August 2017

Elevated type I interferon-like activity in a subset of multiple sclerosis patients: molecular basis and clinical relevance (English)

1 reference

13 August 2017

0 references

Alexander Hundeshagen

1 reference

13 August 2017

Michael Hecker

1 reference

13 August 2017

Brigitte Katrin Paap

1 reference

13 August 2017

Charlotte Angerstein

1 reference

13 August 2017

Ole Kandulski

1 reference

13 August 2017

Christian Fatum

1 reference

13 August 2017

Christiane Hartmann

1 reference

13 August 2017

Dirk Koczan

1 reference

13 August 2017

Hans-Juergen Thiesen

1 reference

13 August 2017

Uwe Klaus Zettl

1 reference

13 August 2017

22 June 2012

1 reference

Journal of Neuroinflammation

13 August 2017

1 reference

13 August 2017

1 reference

13 August 2017

140

1 reference

describes a project that uses

13 August 2017

Cytoscape

object named as

Cytoscape

2 references

9 June 2022

https://europepmc.org/search?query=(METHODS:'Cytoscape')

inferred from PubMed Central ID database lookup

CZ Software Mentions: A large dataset of software mentions in the biomedical literature

cites work

An inventory of short term and long term changes in gene expression under interferon β treatment of relapsing remitting MS patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464734

Reassessment of blood gene expression markers for the prognosis of relapsing-remitting multiple sclerosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464734

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464734

Classical immunomodulatory therapy in multiple sclerosis: how it acts, how it works

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464734

MicroRNAs in multiple sclerosis and experimental autoimmune encephalomyelitis.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464734

Immune-mediated CNS diseases: A review on nosological classification and clinical features

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464734

Biomarkers of disease activity in multiple sclerosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464734

Sieving treatment biomarkers from blood gene-expression profiles: a pharmacogenomic update on two types of multiple sclerosis therapy.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464734

Determinants of interferon β efficacy in patients with multiple sclerosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464734

Th17 cell, the new player of neuroinflammatory process in multiple sclerosis.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464734

Major differences in the responses of primary human leukocyte subsets to IFN-beta.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464734

Current and Future Role of Interferon Beta in the Therapy of Multiple Sclerosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464734

Single-nucleotide polymorphisms in response to interferon-beta therapy in multiple sclerosis.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464734

Interferon beta inhibits the Th17 cell-mediated autoimmune response in patients with relapsing-remitting multiple sclerosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464734

Disease protection and interleukin-10 induction by endogenous interferon-β in multiple sclerosis?

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464734

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464734

T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464734

Intracellular toll-like receptors

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464734

Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-beta-1b treatment in relapsing remitting MS.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464734

MicroRNA regulation of IFN-beta protein expression: rapid and sensitive modulation of the innate immune response

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464734

Intrinsic Cellular Defenses against Virus Infection by Antiviral Type I Interferon

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464734

Type I interferons: crucial participants in disease amplification in autoimmunity

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464734

A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464734

Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464734

A longitudinal study of gene expression in healthy individuals

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464734

Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464734

Interferons and viral infections

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464734

Monitoring of multiple sclerosis immunotherapy: from single candidates to biomarker networks.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464734

Interferons: signaling, antiviral and viral evasion

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464734

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464734

Innate immune response to viral infection

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464734

Interferon-inducible antiviral effectors

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464734

Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464734

Interferons at age 50: past, current and future impact on biomedicine

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464734

Novel definition files for human GeneChips based on GeneAnnot

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464734

Human Toll-like receptor-dependent induction of interferons in protective immunity to viruses

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464734

Multiple sclerosis: a complicated picture of autoimmunity.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464734

Interferon, Mx, and viral countermeasures

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464734

An Atomic Model of the Interferon-β Enhanceosome

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464734

The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464734

Interferon signalling network in innate defence

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464734

Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464734

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464734

Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis.

30 September 2017

1 reference

https://api.crossref.org/works/10.1186%2F1742-2094-9-140

Implication of the Toll-like receptor 4 pathway in the response to interferon-β in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1742-2094-9-140

Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1742-2094-9-140

Network analysis of transcriptional regulation in response to intramuscular interferon-β-1a multiple sclerosis treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1742-2094-9-140

Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1742-2094-9-140

Expression and regulation of IFNalpha/beta receptor in IFNbeta-treated patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1742-2094-9-140

A cytokine gene screen uncovers SOCS1 as genetic risk factor for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1742-2094-9-140

MxA Gene Expression Analysis as an Interferon-β Bioactivity Measurement in Patients with Multiple Sclerosis and the Identification of Antibody-Mediated Decreased Bioactivity

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464734

The natural history of secondary progressive multiple sclerosis

22 September 2018

1 reference

https://api.crossref.org/works/10.1186%2F1742-2094-9-140

Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS

21 January 2018

1 reference

12 December 2020

Positive feedback regulation of type I IFN genes by the IFN-inducible transcription factor IRF-7

1 reference

12 December 2020

1 reference

12 December 2020

A subtype of multiple sclerosis defined by an activated immune defense program

1 reference

12 December 2020

Mechanisms for regulation of cellular responsiveness to human IFN-beta1a

1 reference

12 December 2020

TLR7 and TLR8 agonists trigger different signaling pathways for human dendritic cell maturation

1 reference

12 December 2020

Immunology of multiple sclerosis

1 reference

12 December 2020

Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study

1 reference

12 December 2020

Frequency and Magnitude of Interferon β Neutralizing Antibodies in the Evaluation of Interferon β Immunogenicity in Patients with Multiple Sclerosis

1 reference

12 December 2020

Identifiers

DOI

10.1186/1742-2094-9-140

1 reference

Dimensions Publication ID

13 August 2017

0 references

1 reference

13 August 2017

PubMed publication ID

22727118

1 reference